The interview examines persistent unmet needs in pancreatic cancer, highlighting limited advances in outcomes for patients with poor performance status. It discusses the continued reliance on cytotoxic chemotherapy, contrasting institutional practices for resectable, borderline resectable, and locally advanced disease. The conversation also explores the promise of novel targeted and immunotherapeutic approaches, particularly KRAS inhibitors, neoantigen vaccines, and emerging Phase III candidates.

This interview was conducted on 22 July 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.